Gilde Healthcare leads USD 20 million financing round of Belgian sleep therapy company Nyxoah - Gilde Healthcare

Gilde Healthcare leads USD 20 million financing round of Belgian sleep therapy company Nyxoah

7 July 2016

Board will be strengthened with industry experts and Enrique Vega appointed as new CEO

Mont-Saint-Guibert, Belgium – Nyxoah S.A., a medical device company focused on developing a neurostimulation based, disruptive therapy for patients suffering from Obstructive Sleep Apnea (OSA), announced today it has raised €18 million ($20 million) in fresh capital. The financing was led by Gilde Healthcare. SRIW and all existing shareholders also participated in the round. The proceeds will be used to finance Nyxoah’s go-to-market strategy, including CE Mark approval and the US FDA approval process.

The company is pleased to announce the appointment of Enrique Vega as Chief Executive Officer as of September 1st 2016. Mr. Vega is an experienced senior executive with a successful track record in the Cardiac Rhythm Management, Sleep Apnea and Neurostimulation fields. Nyxoah’s board is now composed of:

  • Robert Taub (company co-founder) – Chairman,
  • Janke Dittmer (Partner at Gilde Healthcare) – Vice-Chairman,
  • Jürgen Hambrecht (former CEO of BASF) – Director,
  • Don Deyo (former VP Neuromodulation R&D at Medtronic) – Independent Director and
  • Kevin Rakin (experienced lifescience executive and investor) – Independent Director.

“In Western countries alone there are 5 million OSA patients who require treatment but have failed current gold standard therapy,” said Robert Taub, Nyxoah co-founder and CEO “this large unmet need can be addressed by Nyxoah’s bilateral neurostimulation therapy.”

 

About Nyxoah

Nyxoah S.A. is a medical device company, focused on developing and commercializing a disruptive neurostimulation based therapy for the treatment of Obstructive Sleep Apnea (OSA). Headquartered in Mont-Saint-Guibert, Nyxoah SA was co-founded in 2009 by Robert Taub.

The company has developed the first and only lead-free neurostimulator, capable of delivering bilateral hypoglossal nerve stimulation for moderate to severe OSA patients, who have failed conventional CPAP therapy.

About Gilde Healthcare

Gilde Healthcare (Utrecht, The Netherlands and Cambridge, USA) is a European specialist investment firm focused on private healthcare companies. It has over €800 million ($900 million) under management and is actively looking to lead new investments in digital health, medical devices, therapeutics and healthcare services. Gilde successfully builds healthcare businesses across Europe and US, investing up to €30 million in a single portfolio company. For a list of Gilde’s portfolio companies please visit the website at www.gildehealthcare.com.

Gilde Healthcare Private Equity as part of Investor Consortium acquires DETAX

Specialist for medical polymer materials DETAX resolves ownership succession in the course of a management buy-out and continues its successful growth track together with a strong Investor Consortium DETAX is a leading global supplier of...
3 December 2021

Adcendo Further Strengthens Management Team and Scientific Advisory Board with Appointment of International ADC Leaders

Building the team with experienced biotech experts and renowned leaders in the ADC field Underscores company’s commitment to progressing lead program on novel ADC target uPARAP Adcendo, a biotech company focused on the development of...
1 December 2021

Gilde Healthcare company Sanifit acquired by Vifor Pharma

Vifor Pharma to acquire Sanifit, a clinical-stage cardio-renal biopharmaceutical company focused on treatments for progressive vascular calcification disorders, complementing and strengthening the Group’s growing nephrology portfolio Sanifit’s lead compound, SNF472 is a novel, first-in-class inhibitor...
22 November 2021